A Nagler, N Firman, R Feferman, S Cotev, M Pines and S Shoshan
Department of Bone Marrow Transplantation, Hadassah University Hospital, Israel.

Pulmonary fibrosis is a disorder causing a high mortality rate for which therapeutic options are limited. Therefore, the effect of halofuginone, a novel inhibitor of collagen type I synthesis, on bleomycin-induced pulmonary fibrosis was studied in rats. Pulmonary fibrosis was induced by intraperitoneal injections of bleomycin for seven consecutive days, and halofuginone was administered intraperitoneally every second day during the entire experimental period of 42 d. Collagen determination in the lungs and the examination of histologic sections showed that halofuginone significantly reduced fibrosis relative to the untreated control rats. We conclude that halofuginone is a potent in vivo inhibitor of bleomycin-induced pulmonary fibrosis, and that it may potentially be used as a novel therapeutic agent for the treatment of this dysfunction.

This article has been cited by other articles:

				K. D. Huebner, D. S. Jassal, O. Halevy, M. Pines, and J. E. Anderson Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1550 - H1561. [Abstract] [Full Text] [PDF]

				L. K. McLoon Focusing on fibrosis: halofuginone-induced functional improvement in the mdx mouse model of Duchenne muscular dystrophy Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1505 - H1507. [Full Text] [PDF]

				A. V. Gonzalez, F. Le Bellego, and M. S. Ludwig Imbalance of Receptor-Regulated and Inhibitory Smads in Lung Fibroblasts from Bleomycin-Exposed Rats Am. J. Respir. Cell Mol. Biol., February 1, 2007; 36(2): 206 - 212. [Abstract] [Full Text] [PDF]

				S. Jiang, Q. Zeng, M. Gettayacamin, A. Tungtaeng, S. Wannaying, A. Lim, P. Hansukjariya, C. O. Okunji, S. Zhu, and D. Fang Antimalarial Activities and Therapeutic Properties of Febrifugine Analogs Antimicrob. Agents Chemother., March 1, 2005; 49(3): 1169 - 1176. [Abstract] [Full Text] [PDF]

				T. Yamamoto and K. Nishioka Analysis of the effect of halofuginone on bleomycin-induced scleroderma Rheumatology, May 1, 2002; 41(5): 594 - 596. [Full Text] [PDF]

				M. Elkin, R. Reich, A. Nagler, E. Aingorn, M. Pines, N. de-Groot, A. Hochberg, and I. Vlodavsky Inhibition of Matrix Metalloproteinase-2 Expression and Bladder Carcinoma Metastasis by Halofuginone Clin. Cancer Res., August 1, 1999; 5(8): 1982 - 1988. [Abstract] [Full Text] [PDF]

				A. Nagler, H.-Q. Miao, H. Aingorn, M. Pines, O. Genina, and I. Vlodavsky Inhibition of Collagen Synthesis, Smooth Muscle Cell Proliferation, and Injury-Induced Intimal Hyperplasia by Halofuginone Arterioscler. Thromb. Vasc. Biol., January 1, 1997; 17(1): 194 - 202. [Abstract] [Full Text]